120 results on '"A. Viros"'
Number of results to display per page
Search Results
2. Supplementary Table S2 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 67K,MIG6-ERRFI1 differentially expressed phosphopeptides in A375(X) vs A375(X)/R cells
- Published
- 2023
- Full Text
- View/download PDF
3. Supplementary Material from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 124K, Contains extended Materials and Methods for the manuscript
- Published
- 2023
- Full Text
- View/download PDF
4. Supplementary Figure Legends from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure Legends PDF file - 92K, This file contains the Figure legends to Supplementary Figures 1-5
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary Figure S1 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 64K, Western blotting for phospho-EGFR in tumour xenografts
- Published
- 2023
- Full Text
- View/download PDF
6. Supplementary Figure 2 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure 2 PDF file - 394K,Data are presented to show that congenital expression of NRASG12D in mouse melanocytes does not affect eyes or heart development
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary Table S4 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
40 Gene Miseq primers.
- Published
- 2023
- Full Text
- View/download PDF
8. Supplementary Figure 4 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure 4 PDF file - 39K, Sequencing of RT-PCR amplified cDNA is presented to show that NRASG12D is expressed in the CNS tumors of our mice
- Published
- 2023
- Full Text
- View/download PDF
9. Supplementary Materials, Figures 1-7, Table 1 from Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
- Author
-
Richard Marais, Amaya Viros, Robert Hayward, and Matthew J. Martin
- Abstract
PDF file - 1.6MB
- Published
- 2023
- Full Text
- View/download PDF
10. Supplementary Table S4 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 60K, Proteins with differentially regulated phosphopeptides corresponding to the cytoskeleton group according to DAVID GO analysis
- Published
- 2023
- Full Text
- View/download PDF
11. Supplementary Table S2 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
10 gene Miseq primers.
- Published
- 2023
- Full Text
- View/download PDF
12. Supplementary Figure 5 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure 5 PDF file - 1328K, Histopathology is shown to confirm that the tumors from patients 1 and 2 are melanoma of the CNS and that the congenital nevus from patient 2 expresses NRASQ61K
- Published
- 2023
- Full Text
- View/download PDF
13. Supplementary Table S1 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
ctDNA patient list.
- Published
- 2023
- Full Text
- View/download PDF
14. Supplementary Table S3 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 49K,SFK phosphorylation in BRAF inhibitor-resistant tumours following dasatinib treatment
- Published
- 2023
- Full Text
- View/download PDF
15. Data from Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
- Author
-
Richard Marais, Amaya Viros, Robert Hayward, and Matthew J. Martin
- Abstract
The antidiabetic drug metformin has antitumor activity in a variety of cancers because it blocks cell growth by inhibiting TORC1. Here, we show that melanoma cells that are driven by oncogenic BRAF are resistant to the growth-inhibitory effects of metformin because RSK sustains TORC1 activity even when AMP-activated protein kinase (AMPK) is activated. We further show that AMPK targets the dual-specificity protein phosphatase DUSP6 for degradation and this increases ERK activity, which then upregulates the VEGF-A protein. Critically, this drives angiogenesis and accelerates the growth of BRAF-driven tumors in mice. Unexpectedly, however, when VEGF signaling is inhibited, instead of accelerating tumor growth, metformin inhibits tumor growth. Thus, we show that BRAF-driven melanoma cells are resistant to the antigrowth effects of AMPK and that AMPK mediates cell-autonomous and cell-nonautonomous effects that accelerate the growth of these cells in vivo.Significance: Metformin inhibits the growth of most tumor cells, but BRAF-mutant melanoma cells are resistant to metformin in vitro, and metformin accelerates their growth in vivo. Unexpectedly, VEGF inhibitors and metformin synergize to suppress the growth of BRAF-mutant tumors, revealing a combination of drugs that may be effective in these patients. Cancer Discov; 2(4); 344–55. ©2012 AACR.This article is highlighted in the In This Issue feature, 288
- Published
- 2023
- Full Text
- View/download PDF
16. Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
Supplementary Methods
- Published
- 2023
- Full Text
- View/download PDF
17. Supplementary Table S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
PDXs and WES list.
- Published
- 2023
- Full Text
- View/download PDF
18. Supplementary Table S5 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 44K,SFK phosphorylation intensity in patient sample following treatment with vehicle or dasatinib as indicated
- Published
- 2023
- Full Text
- View/download PDF
19. Supplementary Table S1 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 201K,Differentially expressed phosphopeptides in A375(X) vs A375(X)/R cells
- Published
- 2023
- Full Text
- View/download PDF
20. Supplementary Figure 1 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure 1 PDF file - 795K, Data are presented to show that NRASG12D does not induce melanoma when expressed in the melanocytes of adult mice
- Published
- 2023
- Full Text
- View/download PDF
21. Supplementary Figure Legends from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 77K,Supplementary Figure Legends for Supplementary Figures S1 and S2
- Published
- 2023
- Full Text
- View/download PDF
22. Supplementary Figure S2 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- Author
-
Richard Marais, Claus Jorgensen, James Larkin, Caroline Springer, Paul Lorigan, Martin Gore, Andrew Hayes, John Sinclair, Alfonso Zambon, Dan Niculescu-Duvaz, Samra Turajlic, Amaya Viros, Berta Sanchez-Laorden, Malin Pedersen, and Maria R. Girotti
- Abstract
PDF file - 116K, Photomicrographs showing phospho-EGFR staining in patients' tumours
- Published
- 2023
- Full Text
- View/download PDF
23. Supplementary Figure 3 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
- Author
-
Richard Marais, Willeke A.M. Blokx, Pieter Wesseling, Benno Küsters, Caroline J. Springer, Ion Niculescu-Duvaz, Jolanda Schieving, Willy Renier, Ilse A. van Engen-van Grunsven, Jacobus H. Gilhuis, Berta Sanchez-Laorden, Patricia J.T.A. Groenen, Amaya Viros, Heidi V.N. Küsters-Vandevelde, and Malin Pedersen
- Abstract
Supplementary Figure 3 PDF file - 498K, Histopathology data are presented to confirm that CNS tumors in our mice are malignant melanomas
- Published
- 2023
- Full Text
- View/download PDF
24. Supplementary Table S5 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
CDXs list.
- Published
- 2023
- Full Text
- View/download PDF
25. Supplementary Figure S1 - S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- Author
-
Richard Marais, Caroline Dive, Paul Lorigan, Ged Brady, Nathalie Dhomen, Deemesh Oudit, Alberto Fusi, Matthew Smith, Jacqueline Swan, Jane Rogan, Malin Pedersen, Franziska Baenke, Simon J. Furney, Grazia Saturno, Kok Haw Jonathan Lim, Amit Kumar Mandal, Amaya Viros, Dominic Rothwell, Elena Galvani, Rebecca Lee, Gabriela Gremel, and Maria Romina Girotti
- Abstract
Supplementary Figure S1. IGV visualization for whole exome sequencing of codon Q61 of NRAS in the pre-treatment tumor vs. the relapsed tumor in patient 1. The red color indicates the A>G for the p.Q61R mutation in the tumor. Supplementary Figure S2. A. IGV visualization for the targeted sequencing of BRAF and PI3KCA in patient 6. B. IGV visualization for the targeted sequencing of BRAF and NRAS in patient 7. Supplementary Figure S3. Response of patient 5 PDX to PLX4720.
- Published
- 2023
- Full Text
- View/download PDF
26. Molecular characterization of fast-growing melanomas
- Author
-
Anderson Loundou, Gabriela Gremel, Richard Marais, Martin G. Cook, Caroline Gaudy-Marqueste, Eduardo Nagore, Nicolas Macagno, Piyushkumar A. Mundra, Timothy Budden, Victoria Akhras, L'Houcine Ouafik, Lijing Lin, J.J. Grob, Eric Pellegrino, Rajesh Kumar, Amaya Viros, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Cancer Research UK Manchester Institute, University of Manchester [Manchester], St George’s University Hospitals, Faculty of Biology, Medicine and Health [Manchester, UK], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), and Instituto Valenciano de Oncologia
- Subjects
Oncology ,medicine.medical_specialty ,Skin Neoplasms ,medicine.medical_treatment ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Dermatology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Melanoma ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,0303 health sciences ,business.industry ,Tumor biology ,Fibroblast growth factor receptor 2 ,Prognosis ,medicine.disease ,Methods observational ,3. Good health ,030220 oncology & carcinogenesis ,Mutation ,business ,Adjuvant ,Memory bias ,Rate of growth - Abstract
Background The rate of growth of primary melanoma is a robust predictor of aggressiveness, but the mutational profile of fast-growing melanomas (FGMM) and the potential to stratify patients at high risk of death has not been comprehensively studied. Objective To investigate the epidemiologic, clinical, and mutational profile of primary cutaneous melanomas with a thickness ≥ 1 mm, stratified by rate of growth. Methods Observational prospective study. Deep-targeted sequencing of 40 melanoma driver genes on formalin fixed, paraffin-embedded primary melanoma samples. Comparison of FGMM (rate of growth > 0.5 mm/month) and nonFGMM (rate of growth ≤ 0.5 mm/month). Results Two hundred patients were enrolled, among wom 70 had FGMM. The relapse-free survival was lower in the FGMM group (P = .014). FGMM had a higher number of predicted deleterious mutations within the 40 genes than nonFGMM (P = .033). Ulceration (P = .032), thickness (P = .006), lower sun exposure (P = .049), and fibroblast growth factor receptor 2 (FGFR2) mutations (P = .037) were significantly associated with fast growth. Limitations Single-center study, cohort size, potential memory bias, number of investigated genes. Conclusion Fast growth is linked to specific tumor biology and environmental factors. Ulceration, thickness, and FGFR2 mutations are associated with fast growth. Screening for FGFR2 mutations might provide an additional tool to better identify FGMM, which are probably good candidates for adjuvant therapies.
- Published
- 2022
- Full Text
- View/download PDF
27. Annual Report 2022
- Author
-
Aglieri, Gianluca, Aleksa, Martin, Feito, Diego Alvarez, Carballo, Aitor Amatriain, Andorno, Marco, Angeletti, Massimo, Antoszczuk, Pablo, Zarate, Fernando Aretio, Tortajada, I. Asensi, Auffray, Etiennette, Ballabriga, Rafael, Balutto, Mattia, Bandi, Franco, Higueras, Maria Barba, Barney, David, Baron, Sophie, Baszczyk, Mateusz Karol, Bialas, Wojciech, Biereigel, Stefan, Blomer, Jakob, Bordelius, Aleksandar, Borghello, G., Bouvier, Philippe, Boyer, Francois, Braach, Justus, De Souza Mendes, Eduardo Brandao, Brondolin, Erica, Brunbauer, Florian, Buschmann, Eric, Buytaert, Jan, Byczynski, Wiktor, Cala', Roberto, Campbell, Michael, Caratelli, Alessandro, Carnesecchi, Ricardo, Catinaccio, Andrea, Cecconi, Leonardo, Ceresa, Davide, Lemos, Edgar Cid, Coco, Victor, Collins, Paula, Contiero, Luca, Arena, Maria Cristina, Cure, Benoit, Rivera, Esteban Curras, Dachs, Florian, Dall'Omo, Frederik, D'Ambrosio, Carmelo, Dannheim, Dominik, Dao, Valerio, De Melo, Joao, De Oliveira, Rui, Deng, Wenjing, Detraz, Stephane, Dhaliwal, Jashandeep, Di Castro, Mario, Di Mauro, Antonello, Dias, Matheo, Dobrijevic, Dominik, Martin, Ana Dorda, Dorosz, Piotr, Dort, Katharina, Dudarev, Alexey, Dumps, Raphael, Emiliani, Simone, Faccio, Federico, Francois, Brieuc, Bulling, Anthony Frederick, Frei, Christoph, Gabrielli, Andrea, Gargiulo, Corrado, Gessinger-Befurt, Paul, Gkougkousis, Vagelis, Gluchowska, Weronika, Gose, Melwin, Guida, Roberto, Gustavino, Carlo, Haimberger, Jakob, Halvorsen, Marius, Hasenbichler, Jan, Hawkings, Richard, Hong, Geun Hee, Hegner, Benedikt, Hellenschmidt, Desiree, Heribi, Quassim, Hillemans, Hartmut, Himmerlich, Anja, Ijzermans, Pieter, Jaekel, Martin, Jakobsen, Sune, Jama, Kacper, Janot, Patrick, Janssens, Djunes, Floethner, Karl Jonathan, Joram, Christian, Junique, Antoine, Jurco, Robert, Kaplon, Jan, Keizer, Floris, Kiehn, Moritz, Klekotko, Adam, Kloukinas, Kostas, Kluge, Alex, Krammer, Manfred, Kratochwil, Nicolaus, Kremastiotis, Iraklis, Kucharska, Gabriela, Kugathasan, Thanushan, Kühn, Susanne, Kulis, Szymon, La Rosa, Alessandro, Lalovic, Milana, Laudi, Elisa, Le Blanc, M., Ledey, Gael, Miotto, Giovanna Lehmann, Lemoine, Corentin, Linssen, Lucie, Lisowska, Marta, Gomez, Javier Lopez, Mager, Magnus, Malentacca, Lorenzo, Mandelli, Beatrice, Manolescu, Florentian, Martina, Francesco, Martinazzoli, Loris, Martinengo, Paolo, Vila, Pere Mato, Maulerova, Vendula, Mazzei, Francesco, McAlpine, Lee, Mehl, Bertrand, Mentink, Matthias, Michelis, Stephano, Carceller, Juan Miguel, Leitao, Pedro Miguel Vicente, Mlynarikova, Michaela, Moll, Michael, Moneta, Lorenzo, Muller, Hans, Musa, Luciano, Bandi, Franco Nahuel, Nauman, Axel, Nookala, Anvesh, Olantera, Lauri, Oliveri, Eraldo, Orlandini, Giorgio, Pacifico, Nicola, Padulano, Vincenzo, Pandey, Awanish, Pantaleo, Felice, Pape, Sebastian, Pejasinovic, Risto, Pernegger, Heinz, Petagna, Paolo, Piedigrossi, Didier, Diaz, Francisco Piernas, Piller, Markus, Piro, Francesco, Pizzichemi, Marco, Pizzirusso, Olivier, Poblocki, Marcin, Prousalidi, Thenia, Rebane, Karolina, Reichenbach, Leonhard, Reidt, Felix, Rembser, Christoph, Riedler, Petra, Riegler, Werner, Rigoletti, Gianluca, Moreira, Paulo Rodrigues Simoes, Rodrigues, Alexis, Roloff, Philipp, Ropelewski, Leszek, Rovere, Marco, Sailer, André, Salamani, Dalila, Salomoni, Matteo, Salzburger, Andreas, Sanna, Isabella, Sasikumar, Swathi, Sauli, Fabio, Scarcella, Carmelo, Scharenberg, Lucian, Schindler, Heinrich, Schmidt, Burkhard, Schmidt, Janis, Schneider, Thomas, Schopper, Andreas, Secouet, Pascal, Sharma, Abhishek, Sicking, Eva, Sigaud, Christophe, Singh, Shuvay, Sirskaran, Viros, Snoeys, Walter, Solans, Carlos, Gonzalez, Maria Soledad Molina, Soos, Csaba, Stewart, Graeme A., Suljic, Miljenko, Svhira, Peter, Teixeira, Antonio, Teofili, Lorenzo, Termo, Gennaro, Troska, Jan, Utrobicic, Antonija, Van Beelen, Jacob, Van Rijnbach, Milou, Van Stenis, Miranda, Vasey, Francois, Vaskuri, Anna, Nunez, Marcos Vazquez, Veenhof, Rob, Verzeroli, Mattia, Pinto, Mateus Vicente Barreto, Leitao, Pedro Vicente, Volker, Alexander, Volkl, Valentin, Wanotayaroj, Chaowaroj, Weick, Julian, Wiehe, Moritz, Wilkens, Henric, and Zaborowska, Anna
- Abstract
This report summarises the activities and main achievements of the CERN strategic R&D programme on technologies for future experiments during the year 2022
- Published
- 2023
28. Extension of the R&D Programme on Technologies for Future Experiments
- Author
-
Joram, Christian, Aglieri, Gianluca, Aleksa, Martin, Feito, Diego Alvarez, Carballo, Aitor Amatriain, Andorno, Marco, Angeletti, Massimo, Antoszczuk, Pablo, Zarate, Fernando Aretio, Tortajada, I. Asensi, Auffray, Etiennette, Ballabriga, Rafael, Balutto, Mattia, Bandi, Franco, Higueras, Maria Barba, Barney, David, Baron, Sophie, Baszczyk, Mateusz Karol, Bialas, Wojciech, Biereigel, Stefan, Blomer, Jakob, Bordelius, Aleksandar, Borghello, G., Bouvier, Philippe, Boyer, Francois, Braach, Justus, De Souza Mendes, Eduardo Brandao, Brondolin, Erica, Brunbauer, Florian, Buschmann, Eric, Buytaert, Jan, Byczynski, Wiktor, Cala', Roberto, Campbell, Michael, Caratelli, Alessandro, Carnesecchi, Ricardo, Catinaccio, Andrea, Cecconi, Leonardo, Ceresa, Davide, Lemos, Edgar Cid, Coco, Victor, Collins, Paula, Contiero, Luca, Arena, Maria Cristina, Cure, Benoit, Rivera, Esteban Curras, Dachs, Florian, Dall'Omo, Frederik, D'Ambrosio, Carmelo, Dannheim, Dominik, Dao, Valerio, De Melo, Joao, De Oliveira, Rui, Deng, Wenjing, Detraz, Stephane, Dhaliwal, Jashandeep, Di Castro, Mario, Di Mauro, Antonello, Dias, Matheo, Dobrijevic, Dominik, Martin, Ana Dorda, Dorosz, Piotr, Dort, Katharina, Dudarev, Alexey, Dumps, Raphael, Emiliani, Simone, Faccio, Federico, Francois, Brieuc, Bulling, Anthony Frederick, Frei, Christoph, Gabrielli, Andrea, Gargiulo, Corrado, Gessinger-Befurt, Paul, Gkougkousis, Vagelis, Gluchowska, Weronika, Gose, Melwin, Guida, Roberto, Gustavino, Carlo, Haimberger, Jakob, Halvorsen, Marius, Hasenbichler, Jan, Hawkings, Richard, Hong, Geun Hee, Hegner, Benedikt, Hellenschmidt, Desiree, Heribi, Quassim, Hillemans, Hartmut, Himmerlich, Anja, Ijzermans, Pieter, Jaekel, Martin, Jakobsen, Sune, Jama, Kacper, Janot, Patrick, Janssens, Djunes, Floethner, Karl Jonathan, Junique, Antoine, Jurco, Robert, Kaplon, Jan, Keizer, Floris, Kiehn, Moritz, Klekotko, Adam, Kloukinas, Kostas, Kluge, Alex, Krammer, Manfred, Kratochwil, Nicolaus, Kremastiotis, Iraklis, Kucharska, Gabriela, Kugathasan, Thanushan, Kühn, Susanne, Kulis, Szymon, La Rosa, Alessandro, Lalovic, Milana, Laudi, Elisa, Le Blanc, M., Ledey, Gael, Miotto, Giovanna Lehmann, Lemoine, Corentin, Linssen, Lucie, Lisowska, Marta, Gomez, Javier Lopez, Mager, Magnus, Malentacca, Lorenzo, Mandelli, Beatrice, Manolescu, Florentian, Martina, Francesco, Martinazzoli, Loris, Martinengo, Paolo, Vila, Pere Mato, Maulerova, Vendula, Mazzei, Francesco, McAlpine, Lee, Mehl, Bertrand, Mentink, Matthias, Michelis, Stephano, Carceller, Juan Miguel, Leitao, Pedro Miguel Vicente, Mlynarikova, Michaela, Moll, Michael, Moneta, Lorenzo, Muller, Hans, Musa, Luciano, Bandi, Franco Nahuel, Nauman, Axel, Nookala, Anvesh, Olantera, Lauri, Oliveri, Eraldo, Orlandini, Giorgio, Pacifico, Nicola, Padulano, Vincenzo, Pandey, Awanish, Pantaleo, Felice, Pape, Sebastian, Pejasinovic, Risto, Pernegger, Heinz, Petagna, Paolo, Piedigrossi, Didier, Diaz, Francisco Piernas, Piller, Markus, Piro, Francesco, Pizzichemi, Marco, Pizzirusso, Olivier, Poblocki, Marcin, Prousalidi, Thenia, Rebane, Karolina, Reichenbach, Leonhard, Reidt, Felix, Rembser, Christoph, Riedler, Petra, Riegler, Werner, Rigoletti, Gianluca, Moreira, Paulo Rodrigues Simoes, Rodrigues, Alexis, Roloff, Philipp, Ropelewski, Leszek, Rovere, Marco, Sailer, André, Salamani, Dalila, Salomoni, Matteo, Salzburger, Andreas, Sanna, Isabella, Sasikumar, Swathi, Sauli, Fabio, Scarcella, Carmelo, Scharenberg, Lucian, Schindler, Heinrich, Schmidt, Burkhard, Schmidt, Janis, Schneider, Thomas, Schopper, Andreas, Secouet, Pascal, Sharma, Abhishek, Sicking, Eva, Sigaud, Christophe, Singh, Shuvay, Sirskaran, Viros, Snoeys, Walter, Solans, Carlos, Gonzalez, Maria Soledad Molina, Soos, Csaba, Stewart, Graeme A., Suljic, Miljenko, Svhira, Peter, Teixeira, Antonio, Teofili, Lorenzo, Termo, Gennaro, Troska, Jan, Utrobicic, Antonija, Van Beelen, Jacob, Van Rijnbach, Milou, Van Stenis, Miranda, Vasey, Francois, Vaskuri, Anna, Nunez, Marcos Vazquez, Veenhof, Rob, Verzeroli, Mattia, Pinto, Mateus Vicente Barreto, Leitao, Pedro Vicente, Volker, Alexander, Volkl, Valentin, Wanotayaroj, Chaowaroj, Weick, Julian, Wiehe, Moritz, Wilkens, Henric, and Zaborowska, Anna
- Abstract
we have conceived an extension of the R&D programme covering the period 2024 to 2028, i.e. again a 5-year period, however with 2024 as overlap year. This step was encouraged by the success of the current programme but also by the Europe-wide efforts to launch new Detector R&D collaborations in the framework of the ECFA Detector R&D Roadmap. We propose to continue our R&D programme with the main activities in essentially the same areas. All activities are fully aligned with the ECFA Roadmap and in most cases will be carried out under the umbrella of one of the new DRD collaborations. The program is a mix of natural continuations of the current activities and a couple of very innovative new developments, such as a radiation hard embedded FPGA implemented in an ASIC based on System-on-Chip technology. A special and urgent topic is the fabrication of Al-reinforced super-conducting cables. Such cables are a core ingredient of any new superconducting magnet such as BabyIAXO, PANDA, EIC, ALICE-3 etc. Production volumes are small and demands come in irregular intervals. Industry (world-wide) is no longer able and willing to fabricate such cables. The most effective approach (technically and financially) may be to re-invent the process at CERN, together with interested partners, and offer this service to the community.
- Published
- 2023
29. Generic Analog 8 Bit DAC IP Block in 28nm CMOS for the High Energy Physics Community
- Author
-
Markus Piller, Rafael Ballabriga, Franco Nahuel Bandi, Giulio Borghello, Davide Ceresa, Risto Pejasinovic, Viros Sriskaran, Alicja Michalowska-Forsyth, and Bernd Deutschmann
- Published
- 2022
- Full Text
- View/download PDF
30. Strategic R&D Programme on Technologies for Future Experiments - Annual Report 2021
- Author
-
Aglieri Rinella, Gianluca, Aleksa,Martin, Alvarez Feito,Diego, Andorno,Marco, Angeletti,Massimo, Antoszczuk,Pablo, Asensi Tortajada,I., Auffray Hillemanns, Etiennette, Ballabriga,Raphael, Balutto,Mattia, Bandi,Franco, Barba Higueras,Maria, Barney,David, Baron,Sophie, Barreto Pinto,Mateus, Bastian Van Beelen,Jacob, Baszczyk,Mateusz Karol, Beguin,Marina, Bialas,W., Biereigel,Stefan, Blomer,Jakob, Borghello,G., Braach,Justus, Brandao De Souza Mendes,Eduardo, Brondolin,Erica, Brunbauer,Florian, Buschmann,Eric, Buytaert,Jan, Byczynski,Wiktor, Cala',Roberto, Cambie,Federico, Campbell,Michael, Caratelli,Alessandro, Carnesecchi,F., Catinaccio,Andrea, Cecconi,Leonardo, Ceresa,Davide, Cid Lemos,Edgar, Coco,Victor, Collins,Paula, Contiero,Luca, Corbetta,Mara, Cure,Benoit, Curras Rivera,Esteban, Dachs,Florian, Dall'Omo,Frederik, D'Ambrosio,Carmelo, Dannheim,Dominik, Dao,V., De Melo,Joao, De Oliveira,Rui, Deng,W., Deng,Wenjing, Detraz,Stephane, Di Mauro,Antonello, Dias,Matheo, Dobrijevic,D., Dobrijevic,Dominik, Dorda Martin,A., Dorda Martin,Ana, Dorosz,P., Dort,Katharina, Dudarev,Alexey, Dumps,Raphael, Faccio,Federico, Fernandez Declara,Placido, Fiorenza,Gabriele, Francois,Brieuc, Frederick Bulling ,Anthony, Frei,Christoph, Gabrielli,A., Gargiulo,Corrado, Gessinger-Befurt,Paul, Gkougkousis,Vagelis, Gluchowska,Weronika, Gose,Melwin, Guida,Roberto, Gustavino,C., Haimberger,Jakob, Halvorsen,Marius, Hasenbichler,J., Hawkings,Richard, Hee Hong,Geun, Hellenschmidt,Desiree, Heribi,Quassim, Hillemans,H., Himmerlich,Anja, Ijzermans,Pieter, Janot,Patrick, Janssens,Djunes, Jonathan Floethner ,Karl, Joram,Christian, Kaplon,Jan, Keizer,Floris, Kiehn,Moritz, Klekotko,Adam, Kloukinas,Kostas, Kluge,Alex, Krammer,Manfred, Kratochwil,Nicolaus, Kremastiotis, Iraklis, Kroeger,Jens, Kugathasan,T., La Rosa,Alessandro, Lafuente,Antonio, Lalovic,Milana, Laudi,Elisa, Le Blanc,M., Ledey,Gael, Leitao,M., Linssen,Lucie, Lisowska,Marta, Lopez Gomez,Javier, Maciej Malinowski,Filip, Magatti,Demetrio, Mager,Magnus, Mandelli,Beatrice, Martinazzoli,Loris, Martinengo,Paolo, Mato Vila,Pere, Maulerova,Vendula, Mehl,Bertrand, Mentink,Matthias, Moll,Michael, Muller,Hans, Musa,Luciano, Neroni,Michela, Olantera ,Lauri, Oliveri,Eraldo, Orlandini,Giorgio, Padulano,Vincenzo, Pantaleo,Felice, Pape,Sebastian, Pejasinovic,Risto, Pernegger,Heinz, Petagna,Paolo, Piedigrossi,Didier, Piernas Diaz,Francisco, Piller,Markus, Piro,Francesco, Pizzichemi, Marco, Pizzirusso,Olivier, Prousalidi ,Thenia, Rebane,K., Reidt,F., Rembser,Christoph, Riedler,Petra, Riegler,Werner, Rigoletti,Gianluca, Rodrigues Simoes Moreira,Paulo, Roloff, Philipp Gerhard, Ropelewski,Leszek, Rovere,Marco, Sailer,André, Salamani,Dalila, Salomoni,Matteo, Salzburger,Andreas, Sanna,I., Scarcella ,Carmelo, Scharenberg,Lucian, Schindler,Heinrich, Schmidt,Burkhard, Schmidt,Janis, Schneider,Thomas, Schopper,Andreas, Secouet,Pascal, Sharma,A., Singh,Shuvay, Sirskaran,Viros, Snoeys,Walter, Solans,Carlos, Soledad Molina Gonzalez,Maria, Soos,Csaba, Stewart,Graeme A, Suljic,M., Svhira,Peter, Teixeira,Antonio, Teofili,Lorenzo, Termo,Gennaro, Troska,Jan, Utrobicic,Antonija, Van Rijnbach,Milou, Van Stenis,Miranda, Vasey,Francois, Vaskuri,Anna, Veenhof,Rob, Verzeroli,Mattia, Vicente Leitao,Pedro, Vicente,M., Volkl,Valentin, Wanotayaroj,Chaowaroj, Weick,Julian, Wiehe,Moritz, and Zaborowska,Anna
- Abstract
This report summarises the activities and main achievements of the CERN strategic R&D programme on technologies for future experiments during the year 2021.
- Published
- 2022
31. Learning Comes from Experience: The Effects on Human Learning and Performance of a Virtual Assistant for Design Space Exploration
- Author
-
Antoni Viros i Martin and Daniel Selva
- Published
- 2022
- Full Text
- View/download PDF
32. Effectiveness of telemedicine in patients with heart failure according to frailty phenotypes: insights from the iCOR randomised controlled trial
- Author
-
C. Enjuanes Grau, N Jose Bazan, A Garay Melero, S Yun Viladomat, E Calero Molina, Santiago Jiménez-Marrero, E Hidalgo Quiros, P Moliner Borja, Josep Comin-Colet, X Corbella Viros, and L Alcoberro Torres
- Subjects
medicine.medical_specialty ,Telemedicine ,Randomized controlled trial ,business.industry ,law ,Heart failure ,medicine ,In patient ,Cardiology and Cardiovascular Medicine ,medicine.disease ,Intensive care medicine ,business ,law.invention - Abstract
Background/Introduction The potential impact of telemedicine (TM) in the monitoring of heart failure (HF) patients is still uncertain, largely due to the heterogeneity of the studies published to date. A subgroup of patients in which its key role is particularly uncertain is that of the frailest patients mainly due to TM-based strategies have been often discouraged on the basis of a foreseeable limited benefit in them. Purpose The aim of this study was to define the efficacy of a TM-based managed care solution across different HF patient frailty phenotypes in a cohort of HF patients recruited in a randomized clinical trial (The Insuficiència Cardíaca Optimitzaciό Remota [iCOR] study) evaluating the efficacy of a TM-based management compared to usual care (UC) in the early post-discharge period. Methods Five previously described frailty clusters were analysed. Cox proportional-hazards regression models were used to evaluate the effect of each cluster and group of treatment (and its interaction) on a series of endpoints (the incidence of non-fatal HF events as primary endpoint and all-cause hospitalization, all-cause death and the composite endpoint combining of all-cause death or non-fatal HF events as secondary endpoints). The incidence proportion of the first occurrence of each of the study endpoints was calculated for each study arm and for cluster, and these compared using χ2 tests. Additionally, a survival analysis was conducted using Cox regression to describe the event-free survival experience of the combination of the clusters with each of the 2 treatment groups for the study endpoints evaluated, and p-value was used to compare the different curves. Results The positive effect of TM compared to UC strategy was consistent across all frailty phenotypes (p-value for interaction 0.711). The risk of experiencing a primary event was significantly lower in patients that underwent allocation to the TM arm compared to UC (p-value=0.016). As shown for the primary endpoint, the positive effect of TM compared to UC strategy was consistent across all frailty phenotypes also for the secondary endpoints (all p-value for interaction >0.05). Likewise, the risk of all-cause hospitalization or the composite end-point of all-cause death or non-fatal HF event was significantly lower in patients that underwent allocation to the TM arm compared to UC (p-value=0.030 and 0.016 respectively). However, the risk of all-cause death did not differ across subgroup strata (p-value>0.05). Conclusion(s) This study showed that non-invasive TM-based follow-up tools are effective compared to UC in preventing fatal and non-fatal adverse events in the early post-discharge period, regardless of the 5 different frailty phenotypes. Importantly, when comparing TM-based follow-up with UC management in patients belonging to equal frailty cluster, those who were followed-up by eHealth had a considerably lower risk of non-fatal HF events, hospitalization or death. Funding Acknowledgement Type of funding sources: None. Cox regression non-fatal HF eventsCox regression all-cause hospitalization
- Published
- 2021
- Full Text
- View/download PDF
33. Frailty phenotypes in patients with heart failure in the early post-discharge period: insights from the iCOR randomised controlled trial and a machine learning-based clustering analysis
- Author
-
Santiago Jiménez-Marrero, S Yun Viladomat, A Garay Melero, X Corbella Viros, N Jose Bazan, P Moliner Borja, Josep Comin-Colet, E Calero Molina, E Hidalgo Quiros, L Aloberro Torres, and C. Enjuanes Grau
- Subjects
medicine.medical_specialty ,Post discharge ,business.industry ,Period (gene) ,medicine.disease ,law.invention ,Randomized controlled trial ,law ,Heart failure ,Emergency medicine ,medicine ,In patient ,Cardiology and Cardiovascular Medicine ,Cluster analysis ,business - Abstract
Background/Introduction Several variables such as clinical, socioeconomic, functional or cognitive, among others can have an impact on the prognosis of heart failure (HF) patients despite the optimisation of follow-up strategies (e.g. telemedicine [TM] solutions). The clustering of HF patients may to identify different patient frailty phenotypes. Purpose The aim of this study was to perform a machine learning-based clustering analysis to identify different patient frailty phenotypes in a cohort of HF patients recruited in a randomized clinical trial (The Insuficiència Cardíaca Optimitzaciό Remota [iCOR] study). Methods We performed the clustering analysis on the basis of 8 frailty-related dimensions. To define the number of clusters, dissimilarity matrix was calculated with Gower's distance. Then, hierarchical divisive clustering was performed. Using then Elbow and Silhouette to analyse how the within sum of squares changes for the different number of clusters, the final number of clusters were chosen. The incidence proportion of the each of the study endpoints (non-fatal HF events as primary endpoint and all-cause hospitalization, all-cause death and the composite endpoint combining of all-cause death or non-fatal HF events as secondary endpoints) was calculated for cluster. Results 5 different frailty phenotypes were identified. Cluster 1 (29 patients, 16%) comprised patients with the best reported self-perceived health status (QoL), fair emotional-affective status, but low levels of self-care. Cluster 2 (41 patients, 23%) included the youngest patients with the highest level of education and a better level of cognition. Cluster 3 (68, 38%) encompassed the patients who had the best level of self-care behaviour (18.9±9.8), greater physical and instrumental functioning for activities of daily living (ADL) and a lower rate of comorbidities. Patients in the Cluster 4 (30 patients, 17%) tended to be elderly females with poor health-related QoL, and a higher level of functional dependence. Finally, Cluster 5 was the smallest group (10 patients, 6%), encompassing the oldest patients with low level of education, a worse affective-emotional state, a significant cognitive decline and a higher proportion of comorbidities compared to the other clusters. Cluster 4 had the highest incidence rate of the primary endpoint (57 per 100 patient-years at risk, 95% CI [37.4–74–5]) and a higher incidence of all-cause hospitalization and of the combined variable of all-cause of death or non-fatal HF events. Conclusion(s) Using the cluster analysis, we were able to stratify HF patients according to the stage of their impairment and vulnerability in each of the different frailty domains. This will allow clinicians to incorporate holistic multi-domain assessments in HF programmes to identify patients' needs and provide each patient with personalised and structured follow-up programme according to patient's needs (personalised and precision medicine). Funding Acknowledgement Type of funding sources: None. Radar chart to compare frailty clustersClinical endpoints according clusters
- Published
- 2021
- Full Text
- View/download PDF
34. Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma
- Author
-
Rajesh Kumar, Amaya Viros, and Eduardo Nagore
- Subjects
Telomerase ,business.industry ,Melanoma ,Immune checkpoint inhibitors ,Immunity ,Improved survival ,Cell Biology ,Dermatology ,Th1 Cells ,medicine.disease ,Biochemistry ,Immune system ,Cancer research ,Medicine ,Humans ,Immunotherapy ,Th1 response ,business ,Molecular Biology - Abstract
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.
- Published
- 2021
35. A Framework to Study Human-AI Collaborative Design Space Exploration
- Author
-
Antoni Viros-i-Martin and Daniel Selva
- Subjects
Computer science ,Human–computer interaction ,Complex system ,Collaborative design ,Space exploration - Abstract
This paper presents a framework to describe and explain human-machine collaborative design focusing on Design Space Exploration (DSE), which is a popular method used in the early design of complex systems with roots in the well-known design as exploration paradigm. The human designer and a cognitive design assistant are both modeled as intelligent agents, with an internal state (e.g., motivation, cognitive workload), a knowledge state (separated in domain, design process, and problem specific knowledge), an estimated state of the world (i.e., status of the design task) and of the other agent, a hierarchy of goals (short-term and long-term, design and learning goals) and a set of long-term attributes (e.g., Kirton’s Adaption-Innovation inventory style, risk aversion). The framework emphasizes the relation between design goals and learning goals in DSE, as previously highlighted in the literature (e.g., Concept-Knowledge theory, LinD model) and builds upon the theory of common ground from human-computer interaction (e.g., shared goals, plans, attention) as a building block to develop successful assistants and interactions. Recent studies in human-AI collaborative DSE are reviewed from the lens of the proposed framework, and some new research questions are identified. This framework can help advance the theory of human-AI collaborative design by helping design researchers build promising hypotheses, and design studies to test these hypotheses that consider most relevant factors.
- Published
- 2021
- Full Text
- View/download PDF
36. Experimental Design & Pilot Testing for ECLSS Anomaly Resolution using Daphne-AT Virtual Assistant
- Author
-
Raymond K. W. Wong, Daniel Selva, Oscar Balcells-Quintana, Renee Woodruff, Antoni Viros, Prachi Dutta, Logan Kluis, Ana Diaz-Artiles, Bonnie J. Dunbar, Poonampreet Kaur Josan, Kyle York, Nikita Beebe, and Ada-Rhodes Short
- Subjects
Mission control center ,Spacecraft ,Situation awareness ,business.industry ,Computer science ,Human spaceflight ,Crew ,Context (language use) ,02 engineering and technology ,NASA Deep Space Network ,01 natural sciences ,Aeronautics ,0103 physical sciences ,0202 electrical engineering, electronic engineering, information engineering ,020201 artificial intelligence & image processing ,business ,010303 astronomy & astrophysics ,Life support system - Abstract
The Global Exploration Roadmap provides a pathway for humans to leave lower Earth orbit and develop a sustained presence in cislunar space as well as the lunar surface before embarking on a long journey to Mars. During these crewed Long Duration Exploration Missions (LDEM), communication delays will limit mission control availability to support the crew during critical in-flight anomalies. In order to address this challenge, future human spaceflight operations will benefit from intelligent Virtual Assistants (VAs) capable of assisting the crew in detecting, diagnosing, and resolving emergency anomalies. This intelligent technology could increase the probability of mission success and crew safety in emergency scenarios and could improve overall crew performance while operating in the hostile environment of deep space. Daphne-AT is a VA to support crewed LDEM in the context of diagnosing and resolving in-flight anomalies related to the Environmental Control and Life Support System (ECLSS) of a spacecraft. The overall research objective is to investigate the effect of Daphne-AT on human performance, cognitive workload, situational awareness, and trust in autonomous systems. Daphne-AT will be validated using controlled laboratory experiments, and further evaluation will occur during the Human Exploration Research Analog (HERA) C6 research campaign, consisting of four 45-day missions in 2020–21. In this paper, we provide an overview of our first version of Daphne-AT (i.e., baseline version), and discuss the design of anomaly scenarios using NASA's ECLSS simulator and the experimental set up for laboratory experiments. A preliminary within-subjects (i.e., with and without Daphne-AT) experiment was conducted with five human subjects, and preliminary results indicate that the use of Daphne-AT increases performance and decreases cognitive workload in the context of ECLSS anomaly scenarios. The data also show that subjects exhibited trust in using Daphne-AT, while it improved certain aspects of their situational awareness. Our work is part of the Human Capabilities Assessments for Autonomous Missions (HCAAM) Virtual NASA Science Center of Research (VNSCOR) within the NASA Human Research Program, and the ultimate goal is to generate standards and guidelines about how to design such VAs for future LDEMs.
- Published
- 2021
- Full Text
- View/download PDF
37. Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients
- Author
-
Esperanza Manrique-Silva, José Antonio López-Guerrero, David Millán-Esteban, Rajiv Kumar, Eduardo Nagore, Simon J Furney, Zaida García-Casado, Celia Requena, Amaya Viros, Victor Traves, and José Bañuls
- Subjects
Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Databases, Factual ,Kit gene ,Dermatology ,medicine.disease_cause ,World health ,Breslow Thickness ,Internal medicine ,medicine ,Distribution (pharmacology) ,Humans ,Neoplasm Invasiveness ,Family history ,skin and connective tissue diseases ,neoplasms ,Melanoma ,Retrospective Studies ,Mutation ,integumentary system ,business.industry ,Mucosal melanoma ,medicine.disease ,Proto-Oncogene Proteins c-kit ,Spain ,business - Abstract
Background KIT mutations are primarily associated with acral and mucosal melanoma, and have been reported to show higher prevalence in chronic sun-damaged (CSD) than non-CSD melanomas. Objectives To investigate the prevalence of KIT mutations in melanoma according to subtype, and determine the clinical role of such mutations. Material & methods We present results from a study of a Spanish population of 492 melanomas, classified according to the latest World Health Organization (WHO) guidelines. We analysed the mutational status of KIT and correlated with different clinical variables related to sun exposure and family history. Results KIT mutations were significantly more frequent in acral (3/36; 8.3%) and mucosal (4/8; 50%) melanomas than non-acral cutaneous melanomas. No significant difference was observed in KIT mutational status between CSD and non-CSD melanomas. Conclusion Our results suggest that KIT mutations in melanoma tumours are unrelated to the development of nevi or chronic sun damage, but their presence is associated with aggressive melanomas which show ulceration, vascular invasiveness, and increased Breslow thickness. These findings are consistent with those reported by The Cancer Genome Atlas network.
- Published
- 2021
38. Female immunity protects from cutaneous squamous cell carcinoma
- Author
-
Victoria Akhras, Shilpa Gurung, Caroline Gaudy-Marqueste, Luisa Motta, Timothy Budden, Deemesh Oudit, Lynne Jamieson, Charles H. Earnshaw, Patrick Shenjere, Carlos Caulin, Amelle Ra, Amaya Viros, Simon J Furney, John T. Lear, Sarah Craig, Yuan Hu, and Ruth Green
- Subjects
business.industry ,medicine.medical_treatment ,Cancer ,Immunotherapy ,medicine.disease ,Transcriptome ,Immune system ,Immunity ,Immunology ,Adjuvant therapy ,Carcinoma ,medicine ,business ,Carcinogen - Abstract
Purpose Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to carcinogens and accumulate more damage than women. We present data showing women are more protected from aggressive cutaneous squamous cell carcinoma (cSCC) due to strong immune activation. Methods We explored clinical and molecular sexual disparity in immunocompetent and immunosuppressed patients (N= 738, N=160) with carcinoma cSCC, in FVB/N mice exposed to equal doses of DMBA, and in human keratinocytes by whole exome sequencing, bulk and single cell RNA sequencing. Results We show cSCC is more aggressive in men, and immunocompetent women develop mild cSCC, later in life. To test if sex drives disparity, we exposed male and female mice to equal doses of carcinogen, and found males present more aggressive, metastatic cSCC than females. Critically, females activate cancer immune-related expression pathways and CD4 and CD8 T cell infiltration independently of mutations. In contrast, males increase the rate of mitoses and proliferation in response to carcinogen. Human female skin and keratinocytes also activate immune-cancer fighting pathways and immune cells at ultraviolet radiation-damaged sites. Critically, a compromised immune system leads to high-risk, aggressive cSCC specifically in women. Conclusions This work shows the immune response is sex biased in cSCC, and highlights female immunity offers greater protection than male immunity. Translational relevance Sex bias affects cancer incidence, mortality and therapy response; and the molecular landscape of cancer differs by sex. However, it is not known if the sex discrepancy is due to a difference in behaviour and exposure to carcinogens, or due to sex-linked susceptibility. This work reveals men are inherently more susceptible to cutaneous aggressive squamous cell carcinoma, in contrast to women who activate stronger immune responses when challenged with the same carcinogens. The loss of immunity particularly affects women. Personalised medicine approaches stratify cancer patients by genotype; however, to date, the potential for cancer stratification, prevention strategies and therapy by sex and immune competency has not been explored. These data indicate men require targeted prevention programs and increased monitoring. Furthermore, we provide a rationale to prioritise men and immunosuppressed women for adjuvant therapy and immunotherapy.
- Published
- 2021
- Full Text
- View/download PDF
39. MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSE
- Author
-
Richard Marais, Caroline Gaudy-Marqueste, Timothy Budden, Rajesh Kumar, Amaya Viros, Eduardo Nagore, and Stephen Smith
- Subjects
Neuroblastoma RAS viral oncogene homolog ,Oncology ,medicine.medical_specialty ,Mutation ,IDH1 ,business.industry ,Melanoma ,medicine.medical_treatment ,Immunotherapy ,medicine.disease ,medicine.disease_cause ,Transcriptome ,CDKN2A ,Internal medicine ,medicine ,Age stratification ,business - Abstract
Melanoma mortality particularly affects older patients, and age is a powerful independent predictor of death. The pathogenic mutations and transcriptomic changes associated with poor survival in aged patients are not known.We analyzed 5 cohorts of metastatic (N=324, N=18, N=66) and primary melanomas (N=103, N=30) to establish the effect of age on prognosis, identify age-specific driver genes and transcriptomic changes linked to survival and immunotherapy response.We identify the pathogenic mutations and transcriptomic changes associated with poor survival by age, and show mutations in BRAF, NRAS, CDKN2A or IDH1 identify metastatic and primary melanoma aged patients with worse outcome. In contrast, activation of immune-regulatory pathways is a hallmark of long-term survival. We tested if mutations in genes linked to poor outcome are associated to immunotherapy responders, exploring combinations of agespecific mutations in metastatic immune checkpoint inhibitor aged responders. Strikingly, aged patients with BRAF, NRAS, CDKN2A or IDH1 mutations and high tumor mutation burden treated with immunotherapy have an improved median survival of 12 months. These data highlight the molecular landscape of melanoma varies by age, and age stratification can refine prognosis and therapy rationales. A set of mutations identifies patients at highest risk of death who are likely immunotherapy responders.
- Published
- 2021
- Full Text
- View/download PDF
40. Decentralized Context-Based On-Board Planning for Earth Observation Missions
- Author
-
Hadas Kress-Gazit, Yizhou Sun, Amy Fang, Antoni Viros Martin, Ankur Mehta, Kewei Cheng, Daniel Selva, and Zhaoliang Zheng
- Subjects
On board ,Earth observation ,Computer science ,Systems engineering ,Context based - Published
- 2021
- Full Text
- View/download PDF
41. Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development
- Author
-
Millan-Esteban D, Pena-Chilet M, Garcia-Casado Z, Manrique-Silva E, Requena C, Banuls J, Lopez-Guerrero J, Rodriguez-Hernandez A, Traves V, Dopazo J, Viros A, Kumar R, and Nagore E
- Subjects
melanoma ,etiopathogeny ,mutations ,neoplasms - Abstract
Simple Summary The divergent pathway model established at least two approaches for melanoma development. One was related to a propensity to melanocytic proliferation (nevogenic), and the other was associated with an accumulation of solar damage (CSD). We conducted a retrospective study to examine whether this model had a molecular support using sequencing and bioinformatic tools on a set of cutaneous melanomas corresponding to these two groups. We found that the nevogenic melanomas were associated with mutations in BRAF, while the CSD melanomas were associated with mutations in NF1, ROS1, GNA11, and RAC1. We concluded that nevogenic and CSD melanomas constitute two different biological entities. According to the divergent pathway model, cutaneous melanoma comprises a nevogenic group with a propensity to melanocyte proliferation and another one associated with cumulative solar damage (CSD). While characterized clinically and epidemiologically, the differences in the molecular profiles between the groups have remained primarily uninvestigated. This study has used a custom gene panel and bioinformatics tools to investigate the potential molecular differences in a thoroughly characterized cohort of 119 melanoma patients belonging to nevogenic and CSD groups. We found that the nevogenic melanomas had a restricted set of mutations, with the prominently mutated gene being BRAF. The CSD melanomas, in contrast, showed mutations in a diverse group of genes that included NF1, ROS1, GNA11, and RAC1. We thus provide evidence that nevogenic and CSD melanomas constitute different biological entities and highlight the need to explore new targeted therapies.
- Published
- 2021
42. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register
- Author
-
Mannucci, Pier Mannuccio, Nobili, Alessandro, Pasina, Luca, Tettamanti, Mauro, Franchi, Carlotta, Corrao, Salvatore, Marengoni, Alessandra, Salerno, Francesco, Cesari, Matteo, Perticone, Francesco, Licata, Giuseppe, Violi, Francesco, Corazza, Gino Roberto, Cortesi, Laura, Ardoino, Ilaria, Prisco, Domenico, Silvestri, Elena, Cenci, Caterina, Emmi, Giacomo, Biolo, Gianni, Zanetti, Michela, Guadagni, Martina, Zaccari, Michele, Vanoli, Massimo, Grignani, Giulia, Pulixi, Edoardo Alessandro, Bernardi, Mauro, Bassi, Silvia Li, Santi, Luca, Zaccherini, Giacomo, Mannarino, Elmo, Lupattelli, Graziana, Bianconi, Vanessa, Paciullo, Francesco, Nuti, Ranuccio, Valenti, Roberto, Ruvio, Martina, Cappelli, Silvia, Palazzuoli, Alberto, Olivieri, Oliviero, Girelli, Domenico, Matteazzi, Thomas, Barbagallo, Mario, Dominguez, Ligia, Cocita, Floriana, Beneduce, Vincenza, Plances, Lidia, Zoli, Marco, Lazzari, Ilaria, Brunori, Mattia, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Palasciano, Giuseppe, Modeo, Maria Ester, Di Gennaro, Carla, Cappellini, Maria Domenica, Maira, Diletta, Di Stefano, Valeria, Fabio, Giovanna, Seghezzi, Sonia, Mancarella, Marta, Rossi, Paolo Dionigi, Damanti, Sarah, Clerici, Marta, Conti, Federica, Miceli, Emanuela, Lenti, Marco Vincenzo, Pisati, Martina, Dominioni, Costanza Caccia, Murialdo, Giovanni, Marra, Alessio, Cattaneo, Federico, Secchi, Maria Beatrice, Ghelfi, Davide, Anastasio, Luigi, Sofia, Lucia, Carbone, Maria, Cipollone, Francesco, Guagnano, Maria Teresa, Angelucci, Ermanno, Valeriani, Emanuele, Mancuso, Gerardo, Calipari, Daniela, Bartone, Mosè, Delitala, Giuseppe, Berria, Maria, Muscaritoli, Maurizio, Molfino, Alessio, Petrillo, Enrico, Zuccalà, Giuseppe, D’Aurizio, Gabriella, Romanelli, Giuseppe, Zucchelli, Alberto, Picardi, Antonio, Gentilucci, Umberto Vespasiani, Gallo, Paolo, Dell’Unto, Chiara, Annoni, Giorgio, Corsi, Maurizio, Bellelli, Giuseppe, Zazzetta, Sara, Mazzola, Paolo, Szabo, Hajnalka, Bonfanti, Alessandra, Arturi, Franco, Succurro, Elena, Rubino, Mariangela, Serra, Maria Grazia, Bleve, Maria Antonietta, Gasbarrone, Laura, Sajeva, Maria Rosaria, Brucato, Antonio, Ghidoni, Silvia, Fabris, Fabrizio, Bertozzi, Irene, Bogoni, Giulia, Rabuini, Maria Victoria, Cosi, Elisabetta, Manfredini, Roberto, Fabbian, Fabio, Boari, Benedetta, De Giorgi, Alfredo, Tiseo, Ruana, Paolisso, Giuseppe, Rizzo, Maria Rosaria, Borghi, Claudio, Strocchi, Enrico, De Sando, Valeria, Pareo, Ilenia, Sabbà, Carlo, Vella, Francesco Saverio, Suppressa, Patrizia, Agosti, Pasquale, Schilardi, Andrea, Loparco, Francesca, Fenoglio, Luigi, Bracco, Christian, Giraudo, Alessia Valentina, Fargion, Silvia, Periti, Giulia, Porzio, Marianna, Tiraboschi, Slivia, Peyvandi, Flora, Rossio, Raffaella, Ferrari, Barbara, Colombo, Giulia, Monzani, Valter, Savojardo, Valeria, Folli, Christian, Ceriani, Giuliana, Pallini, Giada, Dallegri, Franco, Ottonello, Luciano, Liberale, Luca, Caserza, Lara, Salam, Kassem, Liberato, Nicola Lucio, Tognin, Tiziana, Bianchi, Giovanni Battista, Giaquinto, Sabrina, Purrello, Francesco, Di Pino, Antonino, Piro, Salvatore, Rozzini, Renzo, Falanga, Lina, Spazzini, Elena, Ferrandina, Camillo, Montrucchio, Giuseppe, Petitti, Paolo, Salmi, Raffaella, Gaudenzi, Piergiorgio, Perri, Ludovica, Landolfi, Raffaele, Montalto, Massimo, Mirijello, Antonio, Guasti, Luigina, Castiglioni, Luana, Maresca, Andrea, Squizzato, Alessandro, Molaro, Marta, Grossi, Alessandra, Bertolotti, Marco, Mussi, Chiara, Libbra, Maria Vittoria, Dondi, Giulia, Pellegrini, Elisa, Carulli, Lucia, COLANGELO, LIDIA, Falbo, Tania, Stanghellini, Vincenzo, De Giorgio, Roberto, Ruggeri, Eugenio, del Vecchio, Sara, Salvi, Andrea, LEONARDI, ROBERTO, Damiani, Giampaolo, Gabrielli, Armando, Capeci, William, Mattioli, Massimo, Martino, Giuseppe Pio, Biondi, Lorenzo, Pettinari, Pietro, Ghio, Riccardo, Col, Anna Dal, Minisola, Salvatore, Colangelo, Luciano, Afeltra, Antonella, Marigliano, Benedetta, Pipita, Maria Elena, Castellino, Pietro, Blanco, Julien, Zanoli, Luca, Pignataro, Samuele, Saracco, Valter, Fogliati, Marisa, Bussolino, Carlo, Mete, Francesca, Gino, Miriam, Cittadini, Antonio, Vigorito, Carlo, Arcopinto, Michele, Salzano, Andrea, Bobbio, Emanuele, Marra, Alberto Maria, Sirico, Domenico, Moreo, Guido, Gasparini, Francesca, Prolo, Silvia, Pina, Gloria, Ballestrero, Alberto, Ferrando, Fabio, Berra, Sergio, Dassi, Simonetta, Nava, Maria Cristina, Graziella, Bruno, Baldassarre, Stefano, Fragapani, Salvatore, Gruden, Gabriella, Galanti, Giorgio, Mascherini, Gabriele, Petri, Cristian, Stefani, Laura, Girino, Margherita, Piccinelli, Valeria, Nasso, Francesco, Gioffrè, Vincenza, DI PASQUALE, MARIA GRAZIA, Scattolin, Giuseppe, Martinelli, Sergio, Turrin, Mauro, Sechi, Leonardo, Catena, Cristina, Colussi, Gianluca, Passariello, Nicola, Rinaldi, Luca, Berti, Franco, Famularo, Giuseppe, Patrizia, Tarsitani, Castello, Roberto, Pasino, Michela, Ceda, Gian Paolo, Maggio, Marcello Giuseppe, Morganti, Simonetta, Artoni, Andrea, Del Giacco, Stefano, Firinu, Davide, Losa, Francesca, Paoletti, Giovanni, Montalto, Giuseppe, Licata, Anna, Malerba, Valentina, Antonino, Lasco, Basile, Giorgio, Antonino, Catalano, Malatino, Lorenzo, Stancanelli, Benedetta, Terranova, Valentina, Di Marca, Salvatore, Mecocci, Patrizia, Ruggiero, Carmelinda, Boccardi, Virginia, Meschi, Tiziana, Lauretani, Fulvio, Ticinesi, Andrea, Minuz, Pietro, Fondrieschi, Luigi, Pirisi, Mario, Fra, Gian Paolo, Sola, Daniele, Porta, Massimo, Riva, Piero, Quadri, Roberto, Scanzi, Giorgio, Mengoli, Caterina, Provini, Stella, Ricevuti, Laura, Simeone, Emilio, Scurti, Rosa, Tolloso, Fabio, Tarquini, Roberto, Valoriani, Alice, Dolenti, Silvia, Vannini, Giulia, Tedeschi, Alberto, Trotta, Lucia, Volpi, Riccardo, Bocchi, Pietro, Vignali, Alessandro, Harari, Sergio, Lonati, Chiara, Cattaneo, Mara, Nieves, Ramirez Duque, Alberto, Muela Molinero, Pedro, Abad Requejo, Vanessa, Lopez Pelaez, Lara, Tamargo, Xavier, Corbella Viros, Francesc, Formiga, Jesus, Diez Manglano, Esperanza, Bejarano Tello, Esther, Del Corral Behamonte, Maria, Sevil Puras, Romero, Manuel, Blanca, Pinilla Llorente, Cristina, Lopez Gonzalez-Cobos, Victoria, Villalba Garcia M., Saez, Lopez, Bosco, Juan, Susana, Sanz Baena, Marta, Arroyo Gallego, Concepcion, Gonzalez Becerra, Antonio, Fernandez Moyano, Hernandez, Mercedes Gomez, Borrego, Manuel Poyato, Raquel, Pacheco Cuadros, Florencia, Perez Rojas, Beatriz, Garcia Olid, Sara, Carrascosa Garcia, Alfonso, Gonzalez-Cruz Cervellera, Marta, Peinado Martinez, Garcia, Sara Carrascosa, Alberto, Ruiz Cantero, Antonio, Albarracín Arraigosa, Montserrat, Godoy Guerrero, Ángel, Barón Ramos Miguel, Manuel, Machin Jose, Ignacio, Novo Veleiro, Lucía, Alvela Suarez, Alfonso, Lopez, David, Rubal Bran, Iria, Iñiguez Vazquez, Monica, Rios Prego, Mannucci, Pier Mannuccio, Nobili, Alessandro, Pasina, Luca, Tettamanti, Mauro, Franchi, Carlotta, Corrao, Salvatore, Marengoni, Alessandra, Salerno, Francesco, Cesari, Matteo, Perticone, Francesco, Licata, Giuseppe, Violi, Francesco, Corazza, Gino Roberto, Cortesi, Laura, Ardoino, Ilaria, Prisco, Domenico, Silvestri, Elena, Cenci, Caterina, Emmi, Giacomo, Biolo, Gianni, Zanetti, Michela, Guadagni, Martina, Zaccari, Michele, Vanoli, Massimo, Grignani, Giulia, Pulixi, Edoardo Alessandro, Bernardi, Mauro, Bassi, Silvia Li, Santi, Luca, Zaccherini, Giacomo, Mannarino, Elmo, Lupattelli, Graziana, Bianconi, Vanessa, Paciullo, Francesco, Nuti, Ranuccio, Valenti, Roberto, Ruvio, Martina, Cappelli, Silvia, Palazzuoli, Alberto, Olivieri, Oliviero, Girelli, Domenico, Matteazzi, Thoma, Barbagallo, Mario, Dominguez, Ligia, Cocita, Floriana, Beneduce, Vincenza, Plances, Lidia, Zoli, Marco, Lazzari, Ilaria, Brunori, Mattia, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Palasciano, Giuseppe, Modeo, Maria Ester, Di Gennaro, Carla, Cappellini, Maria Domenica, Maira, Diletta, Di Stefano, Valeria, Fabio, Giovanna, Seghezzi, Sonia, Mancarella, Marta, Rossi, Paolo Dionigi, Damanti, Sarah, Clerici, Marta, Conti, Federica, Miceli, Emanuela, Lenti, Marco Vincenzo, Pisati, Martina, Dominioni, Costanza Caccia, Murialdo, Giovanni, Marra, Alessio, Cattaneo, Federico, Secchi, Maria Beatrice, Ghelfi, Davide, Anastasio, Luigi, Sofia, Lucia, Carbone, Maria, Cipollone, Francesco, Guagnano, Maria Teresa, Angelucci, Ermanno, Valeriani, Emanuele, Mancuso, Gerardo, Calipari, Daniela, Bartone, Mosè, Delitala, Giuseppe, Berria, Maria, Muscaritoli, Maurizio, Molfino, Alessio, Petrillo, Enrico, Zuccalà, Giuseppe, D’Aurizio, Gabriella, Romanelli, Giuseppe, Zucchelli, Alberto, Picardi, Antonio, Gentilucci, Umberto Vespasiani, Gallo, Paolo, Dell’Unto, Chiara, Annoni, Giorgio, Corsi, Maurizio, Bellelli, Giuseppe, Zazzetta, Sara, Mazzola, Paolo, Szabo, Hajnalka, Bonfanti, Alessandra, Arturi, Franco, Succurro, Elena, Rubino, Mariangela, Serra, Maria Grazia, Bleve, Maria Antonietta, Gasbarrone, Laura, Sajeva, Maria Rosaria, Brucato, Antonio, Ghidoni, Silvia, Fabris, Fabrizio, Bertozzi, Irene, Bogoni, Giulia, Rabuini, Maria Victoria, Cosi, Elisabetta, Manfredini, Roberto, Fabbian, Fabio, Boari, Benedetta, De Giorgi, Alfredo, Tiseo, Ruana, Paolisso, Giuseppe, Rizzo, Maria Rosaria, Borghi, Claudio, Strocchi, Enrico, De Sando, Valeria, Pareo, Ilenia, Sabbà, Carlo, Vella, Francesco Saverio, Suppressa, Patrizia, Agosti, Pasquale, Schilardi, Andrea, Loparco, Francesca, Fenoglio, Luigi, Bracco, Christian, Giraudo, Alessia Valentina, Fargion, Silvia, Periti, Giulia, Porzio, Marianna, Tiraboschi, Slivia, Peyvandi, Flora, Rossio, Raffaella, Ferrari, Barbara, Colombo, Giulia, Monzani, Valter, Savojardo, Valeria, Folli, Christian, Ceriani, Giuliana, Pallini, Giada, Dallegri, Franco, Ottonello, Luciano, Liberale, Luca, Caserza, Lara, Salam, Kassem, Liberato, Nicola Lucio, Tognin, Tiziana, Bianchi, Giovanni Battista, Giaquinto, Sabrina, Purrello, Francesco, Di Pino, Antonino, Piro, Salvatore, Rozzini, Renzo, Falanga, Lina, Spazzini, Elena, Ferrandina, Camillo, Montrucchio, Giuseppe, Petitti, Paolo, Salmi, Raffaella, Gaudenzi, Piergiorgio, Perri, Ludovica, Landolfi, Raffaele, Montalto, Massimo, Mirijello, Antonio, Guasti, Luigina, Castiglioni, Luana, Maresca, Andrea, Squizzato, Alessandro, Molaro, Marta, Grossi, Alessandra, Bertolotti, Marco, Mussi, Chiara, Libbra, Maria Vittoria, Dondi, Giulia, Pellegrini, Elisa, Carulli, Lucia, Colangelo, Lidia, Falbo, Tania, Stanghellini, Vincenzo, De Giorgio, Roberto, Ruggeri, Eugenio, del Vecchio, Sara, Salvi, Andrea, Leonardi, Roberto, Damiani, Giampaolo, Gabrielli, Armando, Capeci, William, Mattioli, Massimo, Martino, Giuseppe Pio, Biondi, Lorenzo, Pettinari, Pietro, Ghio, Riccardo, Col, Anna Dal, Minisola, Salvatore, Colangelo, Luciano, Afeltra, Antonella, Marigliano, Benedetta, Pipita, Maria Elena, Castellino, Pietro, Blanco, Julien, Zanoli, Luca, Pignataro, Samuele, Saracco, Valter, Fogliati, Marisa, Bussolino, Carlo, Mete, Francesca, Gino, Miriam, Cittadini, Antonio, Vigorito, Carlo, Arcopinto, Michele, Salzano, Andrea, Bobbio, Emanuele, Marra, Alberto Maria, Sirico, Domenico, Moreo, Guido, Gasparini, Francesca, Prolo, Silvia, Pina, Gloria, Ballestrero, Alberto, Ferrando, Fabio, Berra, Sergio, Dassi, Simonetta, Nava, Maria Cristina, Graziella, Bruno, Baldassarre, Stefano, Fragapani, Salvatore, Gruden, Gabriella, Galanti, Giorgio, Mascherini, Gabriele, Petri, Cristian, Stefani, Laura, Girino, Margherita, Piccinelli, Valeria, Nasso, Francesco, Gioffrè, Vincenza, Pasquale, Maria, Scattolin, Giuseppe, Martinelli, Sergio, Turrin, Mauro, Sechi, Leonardo, Catena, Cristina, Colussi, Gianluca, Passariello, Nicola, Rinaldi, Luca, Berti, Franco, Famularo, Giuseppe, Patrizia, Tarsitani, Castello, Roberto, Pasino, Michela, Ceda, Gian Paolo, Maggio, Marcello Giuseppe, Morganti, Simonetta, Artoni, Andrea, Del Giacco, Stefano, Firinu, Davide, Losa, Francesca, Paoletti, Giovanni, Montalto, Giuseppe, Licata, Anna, Malerba, Valentina, Antonino, Lasco, Basile, Giorgio, Antonino, Catalano, Malatino, Lorenzo, Stancanelli, Benedetta, Terranova, Valentina, Di Marca, Salvatore, Mecocci, Patrizia, Ruggiero, Carmelinda, Boccardi, Virginia, Meschi, Tiziana, Lauretani, Fulvio, Ticinesi, Andrea, Minuz, Pietro, Fondrieschi, Luigi, Pirisi, Mario, Fra, Gian Paolo, Sola, Daniele, Porta, Massimo, Riva, Piero, Quadri, Roberto, Scanzi, Giorgio, Mengoli, Caterina, Provini, Stella, Ricevuti, Laura, Simeone, Emilio, Scurti, Rosa, Tolloso, Fabio, Tarquini, Roberto, Valoriani, Alice, Dolenti, Silvia, Vannini, Giulia, Tedeschi, Alberto, Trotta, Lucia, Volpi, Riccardo, Bocchi, Pietro, Vignali, Alessandro, Harari, Sergio, Lonati, Chiara, Cattaneo, Mara, Nieves, Ramirez Duque, Alberto, Muela Molinero, Pedro, Abad Requejo, Vanessa, Lopez Pelaez, Lara, Tamargo, Xavier, Corbella Viro, Francesc, Formiga, Jesus, Diez Manglano, Esperanza, Bejarano Tello, Esther, Del Corral Behamonte, Maria, Sevil Pura, Romero, Manuel, Blanca, Pinilla Llorente, Cristina, Lopez Gonzalez-Cobo, Victoria, Villalba Garcia M., Saez, Lopez, Bosco, Juan, Susana, Sanz Baena, Marta, Arroyo Gallego, Concepcion, Gonzalez Becerra, Antonio, Fernandez Moyano, Hernandez, Mercedes Gomez, Borrego, Manuel Poyato, Raquel, Pacheco Cuadro, Florencia, Perez Roja, Beatriz, Garcia Olid, Sara, Carrascosa Garcia, Alfonso, Gonzalez-Cruz Cervellera, Marta, Peinado Martinez, Garcia, Sara Carrascosa, Alberto, Ruiz Cantero, Antonio, Albarracín Arraigosa, Montserrat, Godoy Guerrero, Ángel, Barón Ramos Miguel, Manuel, Machin Jose, Ignacio, Novo Veleiro, Lucía, Alvela Suarez, Alfonso, Lopez, David, Rubal Bran, Iria, Iñiguez Vazquez, Monica, Rios Prego, Pier Mannuccio Mannucci, Alessandro Nobili, Luca Pasina, REPOSI Collaborators [.., Gino Roberto Corazza, Elena Silvestri, Mauro Bernardi, Silvia Li Bassi, Luca Santi, Giacomo Zaccherini, Marco Zoli, Ilaria Lazzari, Mattia Brunori, Claudio Borghi, Enrico Strocchi, Valeria De Sando, Ilenia Pareo, Vincenzo Stanghellini, Roberto De Giorgio, Eugenio Ruggeri, Sara del Vecchio, ], Mannucci, P, Nobili, A, Pasina, L, Dominguez Rodriguez, L, Barbagallo, M, Licata, A, Tettamanti, M, Franchi, C, Corrao, S, Marengoni, A, Salerno, F, Cesari, M, Perticone, F, Licata, G, Violi, F, Corazza, G, Cortesi, L, Ardoino, I, Prisco, D, Silvestri, E, Cenci, C, Emmi, G, Biolo, G, Zanetti, M, Guadagni, M, Zaccari, M, Vanoli, M, Grignani, G, Pulixi, E, Bernardi, M, Bassi, S, Santi, L, Zaccherini, G, Mannarino, E, Lupattelli, G, Bianconi, V, Paciullo, F, Nuti, R, Valenti, R, Ruvio, M, Cappelli, S, Palazzuoli, A, Olivieri, O, Girelli, D, Matteazzi, T, Dominguez, L, Cocita, F, Beneduce, V, Plances, L, Zoli, M, Lazzari, I, Brunori, M, Pasini, F, Capecchi, P, Palasciano, G, Modeo, M, di Gennaro, C, Cappellini, M, Maira, D, di Stefano, V, Fabio, G, Seghezzi, S, Mancarella, M, Rossi, P, Damanti, S, Clerici, M, Conti, F, Miceli, E, Lenti, M, Pisati, M, Dominioni, C, Murialdo, G, Marra, A, Cattaneo, F, Secchi, M, Ghelfi, D, Anastasio, L, Sofia, L, Carbone, M, Cipollone, F, Guagnano, M, Angelucci, E, Valeriani, E, Mancuso, G, Calipari, D, Bartone, M, Delitala, G, Berria, M, Muscaritoli, M, Molfino, A, Petrillo, E, Zuccala, G, D'Aurizio, G, Romanelli, G, Zucchelli, A, Picardi, A, Gentilucci, U, Gallo, P, Dell'Unto, C, Annoni, G, Corsi, M, Bellelli, G, Zazzetta, S, Mazzola, P, Szabo, H, Bonfanti, A, Arturi, F, Succurro, E, Rubino, M, Serra, M, Bleve, M, Gasbarrone, L, Sajeva, M, Brucato, A, Ghidoni, S, Fabris, F, Bertozzi, I, Bogoni, G, Rabuini, M, Cosi, E, Manfredini, R, Fabbian, F, Boari, B, de Giorgi, A, Tiseo, R, Paolisso, G, Rizzo, M, Borghi, C, Strocchi, E, de Sando, V, Pareo, I, Sabba, C, Vella, F, Suppressa, P, Agosti, P, Schilardi, A, Loparco, F, Fenoglio, L, Bracco, C, Giraudo, A, Fargion, S, Periti, G, Porzio, M, Tiraboschi, S, Peyvandi, F, Rossio, R, Ferrari, B, Colombo, G, Monzani, V, Savojardo, V, Folli, C, Ceriani, G, Pallini, G, Dallegri, F, Ottonello, L, Liberale, L, Caserza, L, Salam, K, Liberato, N, Tognin, T, Bianchi, G, Giaquinto, S, Purrello, F, di Pino, A, Piro, S, Rozzini, R, Falanga, L, Spazzini, E, Ferrandina, C, Montrucchio, G, Petitti, P, Salmi, R, Gaudenzi, P, Perri, L, Landolfi, R, Montalto, M, Mirijello, A, Guasti, L, Castiglioni, L, Maresca, A, Squizzato, A, Molaro, M, Grossi, A, Bertolotti, M, Mussi, C, Libbra, M, Dondi, G, Pellegrini, E, Carulli, L, Colangelo, L, Falbo, T, Stanghellini, V, De Giorgio, R, Ruggeri, E, del Vecchio, S, Salvi, A, Leonardi, R, Damiani, G, Gabrielli, A, Capeci, W, Mattioli, M, Martino, G, Biondi, L, Pettinari, P, Ghio, R, Col, A, Minisola, S, Afeltra, A, Marigliano, B, Pipita, M, Castellino, P, Blanco, J, Zanoli, L, Pignataro, S, Saracco, V, Fogliati, M, Bussolino, C, Mete, F, Gino, M, Cittadini, A, Vigorito, C, Arcopinto, M, Salzano, A, Bobbio, E, Sirico, D, Moreo, G, Gasparini, F, Prolo, S, Pina, G, Ballestrero, A, Ferrando, F, Berra, S, Dassi, S, Nava, M, Graziella, B, Baldassarre, S, Fragapani, S, Gruden, G, Galanti, G, Mascherini, G, Petri, C, Stefani, L, Girino, M, Piccinelli, V, Nasso, F, Gioffre, V, Pasquale, M, Scattolin, G, Martinelli, S, Turrin, M, Sechi, L, Catena, C, Colussi, G, Passariello, N, Rinaldi, L, Berti, F, Famularo, G, Patrizia, T, Castello, R, Pasino, M, Ceda, G, Maggio, M, Morganti, S, Artoni, A, Giacco, S, Firinu, D, Losa, F, Paoletti, G, Montalto, G, Malerba, V, Antonino, L, Basile, G, Antonino, C, Malatino, L, Stancanelli, B, Terranova, V, di Marca, S, Mecocci, P, Ruggiero, C, Boccardi, V, Meschi, T, Lauretani, F, Ticinesi, A, Minuz, P, Fondrieschi, L, Pirisi, M, Fra, G, Sola, D, Porta, M, Riva, P, Quadri, R, Scanzi, G, Mengoli, C, Provini, S, Ricevuti, L, Simeone, E, Scurti, R, Tolloso, F, Tarquini, R, Valoriani, A, Dolenti, S, Vannini, G, Tedeschi, A, Trotta, L, Volpi, R, Bocchi, P, Vignali, A, Harari, S, Lonati, C, Cattaneo, M, Nieves, R, Alberto, M, Pedro, A, Vanessa, L, Lara, T, Xavier, C, Francesc, F, Jesus, D, Esperanza, B, Esther, D, Maria, S, Romero, M, Blanca, P, Cristina, L, Victoria, V, Saez, L, Bosco, J, Susana, S, Marta, A, Concepcion, G, Antonio, F, Hernandez, M, Borrego, M, Raquel, P, Florencia, P, Beatriz, G, Sara, C, Alfonso, G, Marta, P, Garcia, S, Alberto, R, Antonio, A, Montserrat, G, Angel, B, Manuel, M, Ignacio, N, Lucia, A, Alfonso, L, David, R, Iria, I, Monica, R, DI PASQUALE, MARIA GRAZIA, di Gennaro, Carla, di Stefano, Valeria, de Giorgi, Alfredo, de Sando, Valeria, di Pino, Antonino, Giacco, Stefano Del, and di Marca, Salvatore
- Subjects
Male ,medicine.medical_specialty ,Population ageing ,Deprescribing ,Inappropriate prescription ,Medication reconciliation ,Multimorbidity ,Polypharmacy ,Population ,Socio-culturale ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,80 and over ,Internal Medicine ,Emergency Medicine ,medicine ,Deprescribing, Inappropriate prescription, Medication reconciliation, Multimorbidity, Polypharmacy ,Humans ,Registries ,030212 general & internal medicine ,Medical prescription ,Adverse effect ,education ,Aged ,Aged, 80 and over ,Geriatrics ,education.field_of_study ,business.industry ,Patient Discharge ,Hospitalization ,Female ,Italy ,Family medicine ,business - Abstract
As a consequence of population aging, we have witnessed in internal medicine hospital wards a progressive shift from a population of in-patients relatively young and mainly affected by a single ailment to one of ever older and more and more complex patients with multiple chronic diseases, followed as out-patients by many different specialists with poor integration andinevitably treated with multiple medications. Polypharmacy (defined as the chronic intake of five or more drugs) is associated with increased risks of drug-drug interactions and related adverse effects, prescription and intake errors, poor compliance, re-hospitalization and mortality. With this background, the Italian Society of Internal Medicine chose to start in 2008 a prospective register called REPOSI (REgistro POliterapie SIMI, Società Italiana di Medicina Interna) in internal medicine and geriatric hospital wards. The country wide register is an ongoing observatory on multimorbidity and polypharmacy in the oldest old, with the goal to improve prescription appropriateness and, thus to avoid potentially inappropriate medications. The main findings of the register, that has accrued so far, 7005 older patients throughout a 10year period, are summarized herewith, with special emphasis on the main patterns of poor prescription appropriateness and related risks of adverse events.
- Published
- 2018
- Full Text
- View/download PDF
43. Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients
- Author
-
Gallo, Paolo, De Vincentis, Antonio, Pedone, Claudio, Nobili, Alessandro, Tettamanti, Mauro, Gentilucci, Umberto Vespasiani, Picardi, Antonio, Mannucci, Pier Mannuccio, Incalzi, Raffaele Antonelli, Prisco, Domenico, Silvestri, Elena, Emmi, Giacomo, Bettiol, Alessandra, Caterina, Cenci, Biolo, Gianni, Zanetti, Michela, Guadagni, Martina, Zaccari, Michele, Chiuch, Massimiliano, Vanoli, Massimo, Grignani, Giulia, Pulixi, Edoardo Alessandro, Bernardi, Mauro, Bassi, Silvia Li, Santi, Luca, Zaccherini, Giacomo, Lupattelli, Graziana, Mannarino, Elmo, Bianconi, Vanessa, Paciullo, Francesco, Alcidi, Riccardo, Nuti, Ranuccio, Valenti, Roberto, Ruvio, Martina, Cappelli, Silvia, Palazzuoli, Alberto, Girelli, Domenico, Busti, Fabiana, Marchi, Giacomo, Barbagallo, Mario, Dominguez, Ligia, Cocita, Floriana, Beneduce, Vincenza, Plances, Lidia, Corrao, Salvatore, Natoli, Giuseppe, Mularo, Salvatore, Raspanti, Massimo, Cavallaro, Federica, Zoli, Marco, Lazzari, Ilaria, Brunori, Mattia, Fabbri, Elisa, Magalotti, Donatella, Arno, Raffaella, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Palasciano, Giuseppe, Modeo, Maria Ester, Di Gennaro, Carla, Cappellini, Maria Domenica, Maira, Diletta, Di Stefano, Valeria, Fabio, Giovanna, Seghezzi, Sonia, Mancarella, Marta, De Amicis, Margherita Migone, De Luca, Giacomo, Scaramellini, Natalia, Cesari, Matteo, Rossi, Paolo Dionigi, Damanti, Sarah, Clerici, Marta, Conti, Federica, Bonini, Giulia, Ottolini, Barbara Brignolo, Di Sabatino, Antonio, Miceli, Emanuela, Lenti, Marco Vincenzo, Pisati, Martina, Dominioni, Costanza Caccia, Murialdo, Giovanni, Marra, Alessio, Cattaneo, Federico, Pontremoli, Roberto, Beccati, Valentina, Nobili, Giulia, Secchi, Maria Beatrice, Ghelfi, Davide, Anastasio, Luigi, Sofia, Lucia, Carbone, Maria, Cipollone, Francesco, Guagnano, Maria Teresa, Valeriani, Emanuele, Rossi, Ilaria, Mancuso, Gerardo, Calipari, Daniela, Bartone, Mose, Delitala, Giuseppe, Berria, Maria, Pes, Chiara, Delitala, Alessandro, Muscaritoli, Maurizio, Molfino, Alessio, Petrillo, Enrico, Zuccala, Giuseppe, D'Aurizio, Gabriella, Romanelli, Giuseppe, Marengoni, Alessandra, Zucchelli, Alberto, Manzoni, Francesca, Volpini, Andrea, Dell'Unto, Chiara, Annoni, Giorgio, Corsi, Maurizio, Bellelli, Giuseppe, Zazzetta, Sara, Mazzola, Paolo, Szabo, Hajnalka, Bonfanti, Alessandra, Arturi, Franco, Succurro, Elena, Rubino, Mariangela, Tassone, Bruno, Sesti, Giorgio, Serra, Maria Grazia, Bleve, Maria Antonietta, Gasbarrone, Laura, Sajeva, Maria Rosaria, Brucato, Antonio, Ghidoni, Silvia, Fabris, Fabrizio, Bertozzi, Irene, Bogoni, Giulia, Rabuini, Maria Victoria, Cosi, Elisabetta, Scarinzi, Paolo, Amabile, Annalisa, Omenetto, Elisabetta, Prandini, Tancredi, Manfredini, Roberto, Fabbian, Fabio, Boari, Benedetta, De Giorgi, Alfredo, Tiseo, Ruana, De Giorgio, Roberto, Paolisso, Giuseppe, Rizzo, Maria Rosaria, Borghi, Claudio, Strocchi, Enrico, Ianniello, Eugenia, Soldati, Mario, Sabba, Carlo, Vella, Francesco Saverio, Suppressa, Patrizia, Agosti, Pasquale, Schilardi, Andrea, Loparco, Francesca, De Vincenzo, Giovanni Michele, Comitangelo, Alessio, Amoruso, Emanuele, Fenoglio, Luigi, Falcetta, Andrea, Bracco, Christian, Fracanzani, Anna L., Fargion, Silvia, Tiraboschi, Silvia, Cespiati, Annalisa, Oberti, Giovanna, Sigon, Giordano, Peyvandi, Flora, Rossio, Raffaella, Ferrari, Barbara, Colombo, Giulia, Monzani, Valter, Savojardo, Valeria, Folli, Christian, Ceriani, Giuliana, Salerno, Francesco, Pallini, Giada, Dallegri, Franco, Ottonello, Luciano, Liberale, Luca, Caserza, Lara, Salam, Kassem, Liberato, Nicola Lucio, Tognin, Tiziana, Bianchi, Giovanni Battista, Giaquinto, Sabrina, Purrello, Francesco, Di Pino, Antonino, Piro, Salvatore, Rozzini, Renzo, Falanga, Lina, Spazzini, Elena, Ferrandina, Camillo, Montrucchio, Giuseppe, Petitti, Paolo, Peasso, Paolo, Favale, Edoardo, Poletto, Cesare, Salmi, Raffaella, Gaudenzi, Piergiorgio, Violi, Francesco, Perri, Ludovica, Landolfi, Raffaele, Montalto, Massimo, Mirijello, Antonio, Guasti, Luigina, Castiglioni, Luana, Maresca, Andrea, Squizzato, Alessandro, Campiotti, Leonardo, Grossi, Alessandra, Bertolotti, Marco, Mussi, Chiara, Lancellotti, Giulia, Libbra, Maria Vittoria, Dondi, Giulia, Pellegrini, Elisa, Carulli, Lucia, Galassi, Matteo, Grassi, Yasmine, Perticone, Francesco, Perticone, Maria, Battaglia, Rosa, Filice, Marco, Maio, Raffaele, Stanghellini, Vincenzo, Ruggeri, Eugenio, del Vecchio, Sara, Salvi, Andrea, Leonardi, Roberto, Damiani, Giampaolo, Capeci, William, Gabrielli, Armando, Mattioli, Massimo, Martino, Giuseppe Pio, Biondi, Lorenzo, Pettinari, Pietro, Ghio, Riccardo, Dal Col, Anna, Minisola, Salvatore, Colangelo, Luciano, Cilli, Mirella, Labbadia, Giancarlo, Afeltra, Antonella, Marigliano, Benedetta, Pipita, Maria Elena, Castellino, Pietro, Zanoli, Luca, Pignataro, Samuele, Gennaro, Alfio, Blanco, Julien, Saracco, Valter, Fogliati, Marisa, Bussolino, Carlo, Mete, Francesca, Gino, Miriam, Cittadini, Antonio, Vigorito, Carlo, Arcopinto, Michele, Salzano, Andrea, Bobbio, Emanuele, Marra, Alberto Maria, Sirico, Domenico, Moreo, Guido, Gasparini, Francesca, Prolo, Silvia, Pina, Gloria, Ballestrero, Alberto, Ferrando, Fabio, Berra, Sergio, Dassi, Simonetta, Nava, Maria Cristina, Graziella, Bruno, Baldassarre, Stefano, Fragapani, Salvatore, Gruden, Gabriella, Galanti, Giorgio, Mascherini, Gabriele, Petri, Cristian, Stefani, Laura, Girino, Margherita, Piccinelli, Valeria, Nasso, Francesco, Gioffre, Vincenza, Pasquale, Maria, Scattolin, Giuseppe, Martinelli, Sergio, Turrin, Mauro, Sechi, Leonardo, Catena, Cristina, Colussi, Gianluca, Passariello, Nicola, Rinaldi, Luca, Berti, Franco, Famularo, Giuseppe, Tarsitani, Patrizia, Castello, Roberto, Pasino, Michela, Ceda, Gian Paolo, Maggio, Marcello Giuseppe, Morganti, Simonetta, Artoni, Andrea, Del Giacco, Stefano, Firinu, Davide, Losa, Francesca, Paoletti, Giovanni, Costanzo, Giulia, Montalto, Giuseppe, Licata, Anna, Malerba, Valentina, Montalto, Filippo Alessandro, Lasco, Antonino, Basile, Giorgio, Catalano, Antonino, Malatino, Lorenzo, Stancanelli, Benedetta, Terranova, Valentina, Di Marca, Salvatore, Di Quattro, Rosario, La Malfa, Lara, Caruso, Rossella, Mecocci, Patrizia, Ruggiero, Carmelinda, Boccardi, Virginia, Meschi, Tiziana, Lauretani, Fulvio, Ticinesi, Andrea, Nouvenne, Antonio, Minuz, Pietro, Fondrieschi, Luigi, Pirisi, Mario, Fra, Gian Paolo, Sola, Daniele, Porta, Massimo, Riva, Piero, Quadri, Roberto, Larovere, Erica, Novelli, Marco, Scanzi, Giorgio, Mengoli, Caterina, Provini, Stella, Ricevuti, Laura, Simeone, Emilio, Scurti, Rosa, Tolloso, Fabio, Tarquini, Roberto, Valoriani, Alice, Dolenti, Silvia, Vannini, Giulia, Tedeschi, Alberto, Trotta, Lucia, Volpi, Riccardo, Bocchi, Pietro, Vignali, Alessandro, Harari, Sergio, Lonati, Chiara, Cattaneo, Mara, Duque Nieves, Ramirez, Molinero Alberto, Muela, Requejo Pedro, Abad, Pelaez Vanessa, Lopez, Lara, Tamargo, Viros Xavier, Corbella, Francesc, Formiga, Manglano Jesus, Diez, Tello Esperanza, Bejarano, Behamonte Esther, Del Corral, Puras Maria, Sevil, Romero, Manuel, Llorente Blanca, Pinilla, Gonzalez-Cobos Cristina, Lopez, Victoria, Villalba Garcia M., Saez, Lopez, Bosco, Juan, Baena Susana, Sanz, Gallego Marta, Arroyo, Becerra Concepcion, Gonzalez, Moyano Antonio, Fernandez, Gomez Hernandez, Mercedes, Poyato Borrego, Manuel, Cuadros Raquel, Pacheco, Rojas Florencia, Perez, Olid Beatriz, Garcia, Garcia Sara, Carrascosa, Cervellera Alfonso, Gonzalez-Cruz, Martinez Marta, Peinado, Cantero Alberto, Ruiz, Arraigosa Antonio, Albarracin, Guerrero Montserrat, Godoy, Miguel Angel, Baron Ramos, Jose Manuel, Machin, Veleiro Ignacio, Novo, Suarez Lucia, Alvela, Alfonso, Lopez, Bran David, Rubal, Vazquez Iria, Iniguez, and Prego Monica, Rios
- Subjects
Male ,medicine.medical_specialty ,Population ,Socio-culturale ,Renal function ,Disease ,030204 cardiovascular system & hematology ,Elderly in-patients ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Acute care ,Epidemiology ,eGFR ,80 and over ,Internal Medicine ,medicine ,Humans ,Renal Insufficiency ,Hospital Mortality ,030212 general & internal medicine ,Renal Insufficiency, Chronic ,Chronic ,education ,Glomerular filtration rate estimation ,Aged ,Aged, 80 and over ,Estimation ,Creatinine ,education.field_of_study ,business.industry ,Prognosis ,Female ,Italy ,Glomerular Filtration Rate ,Hospitalization ,medicine.disease ,Elderly in-patients, Glomerular filtration rate estimation, Prognosis, eGFR ,chemistry ,business ,Kidney disease - Abstract
The estimated glomerular filtration rate (eGFR) is a predictor of important outcomes and its reduction has been associated with the risk of all-cause mortality in both general population and elderly patients. However while reduced renal function is common in older people, the best method for estimating GFR remains unclear, especially in an acute care setting. Most studies analyzing the accuracy of eGFR in the elderly were carried out in different heterogeneous settings. In this study, we compare the prognostic value of different formulas estimating GFR in predicting the risk of in-hospital morbidity and mortality within 3 months from discharge in elderly hospitalized patients. Data were extracted from “Registro Politerapia Societa Italiana di Medicina Interna (REPOSI)”. Patients with available creatinine values at hospital admission were selected and eGFR was calculated according to the different formulas: Cockcroft-Gault, Modification of Diet in Renal Disease equation, Chronic Kidney Disease Epidemiology Collaboration, Berlin Initiative Study and Full Age Spectrum. 4621 patients were included in the analysis. Among these, 4.2% and 14.2% died during hospitalization and within 3 months from discharge, respectively. eGFR > 60 ml/min/1.73 m2 at admission was associated with a very low risk of mortality during the hospital stay and within 90 days from discharge, while an eGFR
- Published
- 2018
- Full Text
- View/download PDF
44. Ultraviolet light and melanoma
- Author
-
Amaya Viros, Charles H. Earnshaw, and Sarah Craig
- Subjects
0301 basic medicine ,business.industry ,Somatic cell ,Melanoma ,Disease ,medicine.disease ,Phenotype ,Pathology and Forensic Medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Ultraviolet light ,Cancer research ,Medicine ,business ,Pathological ,Ultraviolet radiation ,Advanced melanoma - Abstract
Melanoma is a clinically heterogeneous disease, and current strategies for treatment of the primary tumour are based on pathological criteria alone. In the recent past, several DNA-sequencing and RNA-sequencing studies of primary and advanced melanoma samples have identified unique relationships between somatic mutations, genomic aberrations, and the genetic fingerprint of ultraviolet radiation (UVR). The recurrent patterns of genomic alterations reveal different disease pathways, drug targets and mechanisms limiting drug response. Here, we examine the known associations between the molecular categories of melanoma and the multidimensional UVR damage. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Published
- 2018
- Full Text
- View/download PDF
45. New insights into naevoid melanomas: a clinicopathological reassessment
- Author
-
Martin G. Cook, Vincenzo De Giorgi, Caroline Gaudy, Megan E. Grant, Senada Koljenović, Eleanor Kissin, Amaya Viros, Kiarash Khosrotehrani, A. Mandal, Gabriela Gremel, Richard Marais, Daniela Massi, Martin C. Mihm, Willeke A. M. Blokx, Nathalie Dhomen, Joost van den Oord, Adèle C. Green, and Pathology
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Histology ,Adolescent ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Biology ,Pathology and Forensic Medicine ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Naevoid melanoma ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,medicine ,Humans ,Child ,Melanoma ,neoplasms ,Aged ,Aged, 80 and over ,Nevus, Pigmented ,Papilloma ,Manchester Cancer Research Centre ,Atypical cells ,ResearchInstitutes_Networks_Beacons/mcrc ,Cancer ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Dermatology ,Superficial spreading melanoma ,Small-cell melanoma ,030220 oncology & carcinogenesis ,Female - Abstract
Aims Because the term ‘naevoid melanoma’ has variable clinical and pathologic interpretations, we aimed to clarify the features of melanomas referred to as naevoid. Methods and Results A review was undertaken of 102 melanomas diagnosed histopathologically as naevoid melanomas and ascertained by European Organisation for Research and Treatment of Cancer Melanoma Group Subcommittee pathologists from their records. We found these could be classified morphologically into 3 groups. Thirteen melanomas were overlying genuine naevi and were therefore excluded. Of the 89 melanomas considered to be naevoid, 11 presented clinically as exophytic papillomatous nodules with little junctional component and composed of small atypical cells showing numerous mitoses and no change with depth; we termed these “papillomatous naevoid” melanomas. The other 78 were flat or only slightly raised and had a superficial spreading melanoma (SSM)-like component with maturation to a small cell, but still atypical, dermal component; we termed these “maturing naevoid” melanomas. We showed that papillomatous and maturing naevoid melanomas also have differing immunochemical profiles. Preliminary clinical follow-up suggested different outcomes for these two naevoid melanoma types. Conclusions Melanomas that have been classified as naevoid melanomas comprise two types with distinct clinical, histopathologic and immunohistochemical features that may also be prognostically significant. This article is protected by copyright. All rights reserved.
- Published
- 2017
- Full Text
- View/download PDF
46. Virtual Assistant for Anomaly Treatment in Long Duration Exploration Missions
- Author
-
Ana Diaz-Artiles, Oscar Balcells-Quintana, Richard S. Whittle, Daniel Selva, Antoni Viros Martin, Bonnie J. Dunbar, Poonampreet Kaur Josan, Nikita Beebe, Prachi Dutta, and Raymond K. W. Wong
- Subjects
Computer science ,Real-time computing ,Anomaly (physics) ,Short duration ,Remote assistance - Published
- 2020
- Full Text
- View/download PDF
47. Explanation Approaches for the Daphne Virtual Assistant
- Author
-
Antoni Viros Martin and Daniel Selva
- Subjects
Computer science ,Human–computer interaction ,Remote assistance - Published
- 2020
- Full Text
- View/download PDF
48. New biomarkers improve stratification of patients with melanoma
- Author
-
Amaya Viros and Sarah Craig
- Subjects
Oncology ,medicine.medical_specialty ,Skin Neoplasms ,business.industry ,Melanoma ,Stratification (water) ,Dermatology ,Original Articles ,medicine.disease ,Internal medicine ,Translational Research ,medicine ,Humans ,Female ,business ,Biomarkers - Abstract
Summary Background The updated American Joint Committee on Cancer (AJCC) staging criteria for melanoma remain unable to identify high‐risk stage I tumour subsets. Objectives To determine the utility of epidermal autophagy and beclin 1 regulator 1 (AMBRA1)/loricrin (AMLo) expression as a prognostic biomarker for AJCC stage I cutaneous melanoma. Methods Peritumoral AMBRA1 expression was evaluated in a retrospective discovery cohort of 76 AJCC stage I melanomas. AMLo expression was correlated with clinical outcomes up to 12 years in two independent powered, retrospective validation and qualification cohorts comprising 379 AJCC stage I melanomas. Results Decreased AMBRA1 expression in the epidermis overlying primary melanomas in a discovery cohort of 76 AJCC stage I tumours was associated with a 7‐year disease‐free survival (DFS) rate of 81·5% vs. 100% survival with maintained AMBRA1 (P < 0·081). Following an immunohistochemistry protocol for semi‐quantitative analysis of AMLo, analysis was undertaken in validation (n = 218) and qualification cohorts (n = 161) of AJCC stage I melanomas. Combined cohort analysis revealed a DFS rate of 98·3% in the AMLo low‐risk group (n = 239) vs. 85·4% in the AMLo high‐risk cohort (n = 140; P < 0·001). Subcohort multivariate analysis revealed that an AMLo hazard ratio (HR) of 4·04 [95% confidence interval (CI) 1·69–9·66; P = 0·002] is a stronger predictor of DFS than Breslow depth (HR 2·97, 95% CI 0·93–9·56; P = 0·068) in stage IB patients. Conclusions Loss of AMLo expression in the epidermis overlying primary AJCC stage I melanomas identifies high‐risk tumour subsets independently of Breslow depth. What's already known about this topic? There is an unmet clinical need for biomarkers of early‐stage melanoma.Autophagy and beclin 1 regulator 1 (AMBRA1) is a proautophagy regulatory protein with known roles in cell proliferation and differentiation, and is a known tumour suppressor.Loricrin is a marker of epidermal terminal differentiation. What does this study add? AMBRA1 has a functional role in keratinocyte/epidermal proliferation and differentiation.The combined decrease/loss of peritumoral AMBRA1 and loricrin is associated with a significantly increased risk of metastatic spread in American Joint Committee on Cancer (AJCC) stage I tumours vs. melanomas, in which peritumoral AMBRA1 and loricrin are maintained, independently of Breslow depth. What is the translational message? The integration of peritumoral epidermal AMBRA1/loricrin biomarker expression into melanoma care guidelines will facilitate more accurate, personalized risk stratification for patients with AJCC stage I melanomas, thereby facilitating stratification for appropriate follow‐up and informing postdiagnostic investigations, including sentinel lymph node biopsy, ultimately resulting in improved disease outcomes and rationalization of healthcare costs., https://doi.org/10.1111/bjd.18658 available online Linked Editorial: https://doi.org/10.1111/bjd.18555
- Published
- 2020
49. Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population
- Author
-
C. Pollan Guisasola, B. Cirauqui Cirauqui, L Pardo Muñoz, C. Viña Soria, D. Viros Porcuna, F Collurá, and R. Mesia Nin
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Reconstructive surgery ,Population ,Alphapapillomavirus ,Head and neck cancer, Oropharyngeal cancer, Reconstructive surgery, Salvage surgery, Squamous cell carcinoma, TORS ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,Transoral robotic surgery ,medicine ,Humans ,Stage (cooking) ,education ,Aged ,Retrospective Studies ,Aged, 80 and over ,Salvage Therapy ,education.field_of_study ,Mouth ,business.industry ,Squamous Cell Carcinoma of Head and Neck ,Incidence (epidemiology) ,Head and neck cancer ,Cancer ,Human Papillomavirus Negative ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Deglutition ,Oropharyngeal Neoplasms ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Negative Results - Abstract
Transoral robotic surgery (TORS) is one of the main treatment options for non-locally advanced primary oropharyngeal cancer in the United States. However, its use is more limited in countries with a low incidence of human papillomavirus (HPV), such as Spain, in patients with advanced disease, and as salvage surgery. To shed light on the use and potential benefit of TORS in Spanish patients, we analyzed the functional and oncologic outcomes of TORS as both primary and salvage surgery in a primarily HPV-negative population which is representative of oropharyngeal squamous cell carcinoma (OPSCC) patients in Spain. This is a retrospective analysis of prospectively collected data on OPSCC patients treated with TORS at our center between February 2017 and February 2019. Fifty-four OPSCC patients were included; 79.6% were males and 80.5% were HPV negative. Median age was 62 years. Primary surgery was performed on 73.7% (48.1% stage I–II; 51.9% stage III–IV) and salvage surgery on 25.9% of patients. Positive margin rates were 4.3% for T1–2 and 25.8% for T3–4. None of the stage I–II patients and 27.7% of stage III–IV patients required adjuvant treatment. Reconstructive surgery was performed in 19.2% of all patients. Normal swallowing was achieved in 92.7% of patients at 6 months after surgery. 1- and 2-year survival rates for all patients were 94.5% and 89%, respectively. The overall complication rate was 16.1%. Bleeding occurred in 11.5% of patients. Longer hospitalization time was associated with surgical complications (P = 0.03) and reconstructive surgery (P = 0.03) but not with salvage surgery. TORS is a safe and effective treatment for HPV-negative T1–2 OPSCC patients. The positive margin rate was worse in T3–4 patients, indicating the need for careful patient selection in this subgroup.
- Published
- 2020
50. Exogenous Isoprene Confers Physiological Benefits in a Negligible Isoprene Emitter (
- Author
-
Elena, Ormeño, Justine, Viros, Jean-Philippe, Mévy, Alain, Tonetto, Amélie, Saunier, Anne, Bousquet-Mélou, and Catherine, Fernandez
- Subjects
reactive oxygen species ,allelochemicals ,negligible terpene emitters ,abiotic stress ,oxidative pressure ,Article ,isoprene protection ,water deficit - Abstract
Isoprene, the main volatile released by plants, is known to protect the photosynthetic apparatus in isoprene emitters submitted to oxidative pressures caused by environmental constraints. Whether ambient isoprene contributes to protect negligible plant emitters under abiotic stress conditions is less clear, and no study has tested if ambient isoprene is beneficial during drought periods in plant species that naturally release negligible isoprene emissions. This study examines the effect of exogenous isoprene (20 ppbv) on net photosynthesis, stomatal conductance and production of H2O2 (a reactive oxygen species: ROS) in leaves of Acer monspessulanum (a negligible isoprene emitter) submitted to three watering treatments (optimal, moderate water stress and severe water stress). Results showed that A. monspessulanum exhibited a net photosynthesis increase (+30%) and a relative leaf H2O2 decrease when saplings were exposed to an enriched isoprene atmosphere compared to isoprene-free conditions under moderate water deficit. Such physiological improvement under isoprene exposure was not observed under optimal watering or severe water stress. These findings suggest that when negligible isoprene emitters are surrounded by a very high concentration of isoprene in the ambient air, some plant protection mechanism occurs under moderate water deficit probably related to protection against ROS damage eventually impeding photosynthesis drop.
- Published
- 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.